Effects of cytokines on nitric oxide pathways in human vasculature

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 1, 1999, Pages 89-96

  Bhagat, Kiran ^a   Vallance, Patrick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYTOKINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INTERLEUKIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; ENDOTHELIUM CELL; PARESIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASODILATATION;

ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CYTOKINES; HUMANS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 0032935162     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199901000-00014     Document Type: Review

References (52)

1. 1 Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
2. 2 Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis 1997; 131(Suppl):S3-S4. This paper is an update that follows the original (1987) by the same author on the origins of atherogenesis. It details the inflammatory basis of this disease.
3. 3 Anker SD, Egerer KR, Volk HD, Kox WJ, Poole Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430.
4. 4 Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole Wilson PA, Coats AJ. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. OJM 1998; 91:199-203.
5. 5 Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995; 9:1319-1330.
6. 6 Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(Suppl 2):S9-S12.
7. 7 Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844-2850.
8. 8 Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997; 18:231-240. An excellent and updated review of the role of the endothelium in response to cytokines and in their production.
9. 9 Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153.
10. 10 Kuhns DB, Alvord WG, Gallin JI, Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171:145-152.
11. 11 Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bateremia. J Exp Med 1989; 170:1627-1633.
12. 12 Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989; 53:488-498.
13. 13 Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med 1989; 170:1859-1867.
14. 14 Boujoukos AJ, Martich GD, Supinski E, Suffredini AF. Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J Appl Physiol 1993; 74:3027-3033.
15. 15 Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155:5038-5045.
16. 16 Tashiro H, Shimokawa H, Yamamoto K, Nagano M, Momohara M, Muramatu K, Takeshita A. Monocyte-related cytokines in acute myocardial infarction. Am Heart J 1995; 130:446-452.
17. 17 Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schomig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92:748-755.
18. 18 Guillen I, Blanes M, Gomez Lechon MJ, Castell JV. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995; 269(2 Pt 2):R229-R235.
19. 19 Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med 1995; 43:227-235.
20. 20 Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334:1717-1725.
21. 21 Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachetin. Nature 1985; 316:552-554.
22. 22 Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147.
23. 23 Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Network 1994; 5:517-531.
24. 24 O'Neill LA. Interleukin-1 signal transduction. Int J Clin Lab Res 1995; 25:169-177.
25. 25 Bankers Fulbright JL, Kalli KR, McKean DJ. Interleukin-1 signal transduction. Life Sci 1996; 59:61-83.
26. 26 Romano M. Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-325.
27. 27 Lodato RF, Feig B, Akimaru K, Soma G, Klostergaard J. Hemodynamic evaluation of reconbinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model. J Immunother Emphasis Tumor Immunol 1995; 17:19-29.
28. 28 Mitaka C, Hirata Y, Ichikawa K, Yokoyama K, Emori T, Kanno K, Amaha K. Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. Am J Physiol 1994; 267 (4 Pt 2):H1530-H1536.
29. 29 Redl H, Schlag G, Bahrami S, et al. In: Pathophysiology of shock, sepsis and organ failure. Schlag G, Redl H, (editors): The cytokine network in trauma and sepsis I; TNF and IL-8. Berlin; Springer-Verlag; 1993. pp. 468-490.
30. 30 Fatehi Hassanabad Z, Furman BL, Parratt JR. The effect of endotoxin on sympathetic responses in the rat isolated perfused mesenteric bed: involvement of nitric oxide and cyclo-oxygenase products. Br J Pharmacol 1995; 116:3316-3322.
31. 31 Myers PR, Parker JL, Tanner MA, Adams HR. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock 1994; 1:73-78.
32. 32 Introna M, Colotta F, Sozzani S, Dejana E, Mantovani A. Pro- and anti-inflammatory cytokines: interactions with vascular endothelium. Clin Exp Rheumatol 1994; 12(Suppl 10):S19-S23.
33. 33 Wong JM, Billiar TR. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv Pharmacol 1995; 34:155-170.
34. 34 Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol (Heart and Circulatory physiology) 1998; 44:H416-H421. This is the first paper that provides direct evidence that iNOS mediates impairment of vascular contraction in animals after treatment with endotoxin.
35. 35 Rees D, Monkhouse J, Deakin A, et al. The role of nitric oxide in a conscious mouse model of endotoxin shock [abstract]. Br J Pharmacol 1995; 114-123P.
36. 36 Cook HT, Bune AJ, Jansen AS, Taylor GM, Loi RK, Cattell V. Cellular localization of inducible nitric oxide synthase in experimental endotoxic shock in the rat. Clin Sci 1994; 87:179-186.
37. 37 Robinson NM, Baylis SA, Westmore KR, et al. In situ hybridisation localises inducible nitric oxide synthase mRNA to non-myocyte cells in myocardium during septic shock [abstract]. Eur Heart J 1996; 17:407 (P2195).
38. 38 Saks S, Rosenblum M. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. Immunol Ser 1992; 56:567-587.
39. 39 van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-1627.
40. 40 Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in humans in vivo. Circulation 1997; 96:3042-3047. The first direct in-vivo evidence in humans that TNF-α, IL-1β and IL-6 produce significant endothelial dysfunction.
41. 41 Bhagat K, Hingorani A, Palacios M, Charles I, Vallance P. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovascular Research 1999 (in press). The first in-vivo evidence in humans supporting in-vitro studies [45] showing that IL-1β is capable of profoundly affecting NO production in the absence of iNOS.
42. 42 Stouthard JM, Goey H, de Vries EG, de Mulder PH, Groenewegen A, Pronk L, et al. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 1996; 73:789-793.
43. 43 Thorin-Trescases N, Hamilton CA, Reid JL, McPherson KL, Jardine E, Berg G, et al. Inducible L-arginine/nitric oxide pathway in human internal mammary artery and saphenous vein. Am J Physiol 1995; 268 (3 Pt 2):H1122-H1132.
44. 44 Chester A, Borland J, Buttery L, Mitchell J, Cunningham D, Hafizi S, et al. Induction of nitric oxide synthase in human vascular smooth muscle: interactions between proinflammatory cytokines. Cardiovasc Res 1998; 38:814-821.
45. 45 Rosenkranz Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994; 93:2236-2243.
46. 46 Hibbs JB Jr, Westenfelder C, Taintor R, Zdenek V, Kablitz C, Baranowski RL, et al. Evidence of cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992; 89:867-877.
47. 47 Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effect of a nitric oxide synthesis inhibitor in humans with septic shock. Cardiovasc Res 1994; 28:34-39.
48. 48 Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266 (6 Pt 2):H2535-H2541.
49. 49 Greenberg SS, Xie J, Joseph KO, Kolls J, Summer W. In vivo administration of endotoxin and tumor necrosis factor-alpha produce different effects on constitutive and inducible nitric oxide synthase activity in rat neutrophils and aorta ex vivo. Proc Soc Exp Biol Med 1995; 208:199-208.
50. 50 Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996; 78:58-64.
51. 51 Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73:205-209.
52. 52 Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1-beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leuk Biol 1996;59:489-493.